来特莫韦用于儿童造血干细胞移植受者耐巨细胞病毒挽救治疗的研究
Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.
作者信息
Kilgore Jacob T, Becken Bradford, Varga Matthew G, Parikh Suhag, Prasad Vinod, Lugo Debra, Chang Yeh-Chung
机构信息
Division of Pediatric Infectious Diseases, Duke University, Durham, North Carolina.
Department of Epidemiology, Gillings School of Global Public Health and the Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
出版信息
J Pediatric Infect Dis Soc. 2020 Sep 17;9(4):486-489. doi: 10.1093/jpids/piz050.
Abstract
We present here the first published use of letermovir for the treatment of resistant cytomegalovirus (CMV) in a pediatric patient. A 14-year-old girl underwent a double unrelated umbilical cord blood transplantation to treat her sickle cell disease (hemoglobin SS) and developed ganciclovir-resistant CMV DNAemia with end-organ involvement that was treated successfully with a combination of foscarnet and letermovir. After she was transitioned to letermovir monotherapy for secondary prophylaxis, she developed recurrent DNAemia with laboratory-confirmed ganciclovir, foscarnet, and letermovir resistance.
摘要
我们在此展示了首次发表的来特莫韦用于治疗儿科患者耐药巨细胞病毒（CMV）的案例。一名14岁女孩接受了两次无关供者脐血移植以治疗其镰状细胞病（血红蛋白SS型），并出现了对更昔洛韦耐药的CMV血症且伴有终末器官受累，通过膦甲酸钠和来特莫韦联合治疗成功治愈。在她转为接受来特莫韦单药进行二级预防后，又出现了复发性血症，实验室确认对更昔洛韦、膦甲酸钠和来特莫韦耐药。
相似文献
1
Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.来特莫韦用于儿童造血干细胞移植受者耐巨细胞病毒挽救治疗的研究
J Pediatric Infect Dis Soc. 2020 Sep 17;9(4):486-489. doi: 10.1093/jpids/piz050.
2
Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational study.来特莫韦与更昔洛韦预防在接受异基因造血干细胞移植的青少年患者中的真实世界疗效和安全性：一项单中心观察性研究
Front Cell Infect Microbiol. 2025 Jun 3;15:1558637. doi: 10.3389/fcimb.2025.1558637. eCollection 2025.
3
Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients.来特莫韦用于儿童患者异基因造血干细胞移植后巨细胞病毒预防的疗效和安全性
Drug Des Devel Ther. 2025 Jun 12;19:5059-5069. doi: 10.2147/DDDT.S513383. eCollection 2025.
4
The importance of drug exposure in the development of cytomegalovirus resistance.药物暴露在巨细胞病毒耐药性发展中的重要性。
Int J Antimicrob Agents. 2025 Sep;66(3):107537. doi: 10.1016/j.ijantimicag.2025.107537. Epub 2025 May 13.
5
Letermovir prophylaxis for cytomegalovirus infection in hematopoietic transplantation with post-transplant cyclophosphamide.来特莫韦预防接受移植后环磷酰胺的造血移植受者巨细胞病毒感染。
Medicina (B Aires). 2025;85(3):526-533.
6
Letermovir-inclusive combination therapy for a refractory and resistant infection by cytomegalovirus with UL54 mutation following a hematopoietic stem cell transplant for MHC class II deficiency.对于因MHC II类缺陷接受造血干细胞移植后出现的伴有UL54突变的巨细胞病毒难治性和耐药性感染，采用含来特莫韦的联合治疗。
J Infect Chemother. 2025 Apr;31(4):102627. doi: 10.1016/j.jiac.2025.102627. Epub 2025 Jan 23.
7
Benefits of primary prophylaxis with letermovir in patients after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.来特莫韦对血液系统恶性肿瘤异基因造血干细胞移植患者进行一级预防的益处。
Expert Rev Hematol. 2025 Jul;18(7):561-568. doi: 10.1080/17474086.2025.2509876. Epub 2025 May 23.
8
Efficacy, Safety, and Cost-effectiveness Analysis of Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.抗病毒药物用于异基因造血干细胞移植受者巨细胞病毒预防的疗效、安全性和成本效益分析。
Transplantation. 2024 Apr 1;108(4):1021-1032. doi: 10.1097/TP.0000000000004856. Epub 2023 Dec 5.
9
Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).来特莫韦成功用于一名患有耐更昔洛韦巨细胞病毒综合征（UL97突变）的心脏移植受者的二级预防。
Transpl Infect Dis. 2018 Oct;20(5):e12965. doi: 10.1111/tid.12965. Epub 2018 Jul 20.
10
Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.拉替拉韦耐药导致肺移植受者更昔洛韦耐药巨细胞病毒感染
Am J Transplant. 2018 Dec;18(12):3060-3064. doi: 10.1111/ajt.15135. Epub 2018 Oct 29.
引用本文的文献
1
Cytomegalovirus infection and drug resistance emergence during letermovir salvage therapy in a pediatric SCID patient.一名儿科重症联合免疫缺陷病（SCID）患者在使用来特莫韦挽救治疗期间出现巨细胞病毒感染及耐药情况。
NPJ Antimicrob Resist. 2025 May 28;3(1):43. doi: 10.1038/s44259-025-00118-y.
2
[Refractory or resistant cytomegalovirus infections after hematopoietic stem cell transplantation: diagnosis and management].造血干细胞移植后难治性或耐药性巨细胞病毒感染：诊断与管理
Zhonghua Xue Ye Xue Za Zhi. 2024 Nov 14;45(11):1058-1064. doi: 10.3760/cma.j.cn121090-20240615-00223.
3
The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients.造血干细胞移植患者巨细胞病毒感染的十大常见问题
Clin Hematol Int. 2023 Mar;5(1):21-28. doi: 10.1007/s44228-022-00025-3. Epub 2022 Dec 29.
4
Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients.来特莫韦用于儿科异基因造血细胞移植患者巨细胞病毒感染的预防和先发治疗。
Paediatr Drugs. 2023 Mar;25(2):225-232. doi: 10.1007/s40272-022-00547-6. Epub 2022 Dec 27.
5
Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review.儿科造血干细胞移植受者中人巨细胞病毒的预防与管理：综述
Front Pediatr. 2022 Nov 23;10:1039938. doi: 10.3389/fped.2022.1039938. eCollection 2022.
6
Natural killer cell infusion for cytomegalovirus infection in pediatric patients with Wiskott-Aldrich syndrome following cord blood transplantation: A case report and literature review.脐血移植后患有维斯科特-奥尔德里奇综合征的儿科患者巨细胞病毒感染的自然杀伤细胞输注：病例报告及文献综述
Front Med (Lausanne). 2022 Oct 10;9:988847. doi: 10.3389/fmed.2022.988847. eCollection 2022.
7
Cytomegalovirus in Haematological Tumours.血液肿瘤中的巨细胞病毒。
Front Immunol. 2021 Oct 18;12:703256. doi: 10.3389/fimmu.2021.703256. eCollection 2021.
8
Off-Label Use of Letermovir as Preemptive Anti-Cytomegalovirus Therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant.来特莫韦在儿童异基因外周血干细胞移植中作为抢先抗巨细胞病毒治疗的超说明书用药
Infect Drug Resist. 2021 Mar 23;14:1185-1190. doi: 10.2147/IDR.S296927. eCollection 2021.
9
Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.从更昔洛韦和膦甲酸钠转移：CMV 治疗的进展。
Curr Hematol Malig Rep. 2020 Apr;15(2):90-102. doi: 10.1007/s11899-020-00557-6.
本文引用的文献
1
Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation.异基因造血细胞移植中巨细胞病毒感染的抗病毒预防。
Blood Adv. 2018 Aug 28;2(16):2159-2175. doi: 10.1182/bloodadvances.2018016493.
2
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.来特莫韦预防造血干细胞移植后巨细胞病毒感染。
N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6.
3
Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植后的免疫重建
Front Immunol. 2016 Nov 17;7:507. doi: 10.3389/fimmu.2016.00507. eCollection 2016.
4
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.导致来特莫韦耐药的人巨细胞病毒UL56突变的快速体外进化
Antimicrob Agents Chemother. 2015 Oct;59(10):6588-93. doi: 10.1128/AAC.01623-15. Epub 2015 Aug 10.
5
Cytomegalovirus Treatment.巨细胞病毒治疗
Curr Treat Options Infect Dis. 2014;6(3):256-270. doi: 10.1007/s40506-014-0021-5.
6
Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT.代表 EBMT 的先天错误、传染病和儿科疾病工作组，对儿科异基因 HSCT 项目中的 CMV 管理进行调查。
Bone Marrow Transplant. 2014 Feb;49(2):276-9. doi: 10.1038/bmt.2013.164. Epub 2013 Oct 28.
7
Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.用于治疗巨细胞病毒（CMV）视网膜炎的现有及新型抗病毒药物：近期专利综述
Recent Pat Antiinfect Drug Discov. 2012 Apr;7(1):8-18. doi: 10.2174/157489112799829765.
8
The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.新型抗巨细胞病毒化合物 AIC246（来特莫韦）通过一种特定的抗病毒机制抑制人类巨细胞病毒复制，该机制涉及病毒末端酶。
J Virol. 2011 Oct;85(20):10884-93. doi: 10.1128/JVI.05265-11. Epub 2011 Jul 13.
9
Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.西多福韦用于异基因造血干细胞移植受者的巨细胞病毒感染和疾病。欧洲血液与骨髓移植组传染病工作组。
Blood. 2001 Jan 15;97(2):388-92. doi: 10.1182/blood.v97.2.388.
10
Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro.更昔洛韦与膦甲酸钠对巨细胞病毒体外复制的协同作用。
Antimicrob Agents Chemother. 1990 Feb;34(2):373-5. doi: 10.1128/AAC.34.2.373.
Zotero 插件